Patents Examined by Nancy J Leith
  • Patent number: 11371042
    Abstract: The present invention relates inter alia to expression vector production as well as application to the production of host cells for protein repertoire expression and high-throughput screening. The invention also relates to primers useful for PCR amplification of nucleotide sequences encoding human antibody variable domains.
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: June 28, 2022
    Assignee: Kymab Limited
    Inventors: Allan Bradley, E-Chiang Lee, Qi Liang, Hui Liu, Andrew Wood, Vivian Wong
  • Patent number: 11371040
    Abstract: Provided herein are methods and kits for labeling endonuclease-treated cells. The methods comprise: contacting the cells to be labelled with at least one endonuclease suitable for targeting a genomic region of interest, and first and second nucleic acids suitable for introducing one or more silent (or optionally non-silent) mutation(s) in the genomic region by homology-directed repair (HDR). The mutation(s) introduced by the first nucleic acid differ from the mutation(s) introduced by the second nucleic acid.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: June 28, 2022
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICAL (INSERM), UNIVERSITE DE ROUEN NORMANDIE
    Inventor: Luca Grumolato
  • Patent number: 11365437
    Abstract: The present invention provides, among other things, methods of quantitating mRNA capping efficiency, particularly for mRNA synthesized in vitro. In some embodiments, the methods comprise chromatographic methods of quantifying capping efficiency and methylation status of the caps.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: June 21, 2022
    Assignee: Translate Bio, Inc.
    Inventors: Michael Heartlein, Frank DeRosa, Anusha Dias
  • Patent number: 11359234
    Abstract: Gene expression can be identified by analyzing a DNA sequence. The DNA sequence can include a barcode sequence that corresponds to a particular gene. The barcode sequence can be produced during the expression of a gene by first adding a Homologous Directed Repair (HDR) template including the barcode sequence into the DNA sequence of the gene and then splicing the barcode sequence out of an RNA precursor during the expression of the gene. As the barcode sequence is made available from the RNA precursor, it can be added to the DNA strand using HDR. The resulting DNA strand can be sequenced and the sequence data can be analyzed to identify the barcode sequence within the DNA sequence, which provides an indicator of the expression of the gene in DNA rather than RNA.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: June 14, 2022
    Assignee: MICROSOFT TECHNOLOGY LICENSING, LLC
    Inventor: Kris K. Ganjam
  • Patent number: 11360104
    Abstract: Described herein are methods, compositions and processes related to a microbial-based biosensor system for the detection of small molecules and analytes based on an analyte-responsive transcription factor-DNA binding mechanism with either a ratiometric fluorescent output through Förster resonance energy transfer (FRET) or a redox sensor output for the quantification of the target analyte with high sensitivity.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: June 14, 2022
    Assignees: TRUSTEES OF BOSTON UNIVERSITY, L'UNIVERSITÉ DE BORDEAUX, L'INSTITUT POLYTECHNIQUE DE BORDEAUX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: James Galagan, Allison Dennis, Catherine Klapperich, Mark Grinstaff, Thuy Nguyen, R. Baer, Uros Kuzmanovic, Marjon Zamani, Mingfu Chen, Margaret Chern, Chloe Grazon
  • Patent number: 11352647
    Abstract: Embodiments disclosed herein are directed to engineered CRISPR-Cas effector proteins that comprise at least one modification compared to an unmodified CRISPR-Cas effector protein that enhances binding of the of the CRISPR complex to the binding site and/or alters editing preference as compared to wild type. In certain example embodiments, the CRISPR-Cas effector protein is a Type V effector protein. In certain other example embodiments, the Type V effector protein is Cpf1. Embodiments disclosed herein are directed to viral vectors for delivery of CRISPR-Cas effector proteins, including Cpf1. In certain example embodiments, the vectors are designed so as to allow packaging of the CRISPR-Cas effector protein within a single vector. There is also an increased interest in the design of compact promoters for packing and thus expressing larger transgenes for targeted delivery and tissue-specificity.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: June 7, 2022
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Feng Zhang, David Arthur Scott, Winston Xia Yan, Sourav Choudhury, Matthias Heidenreich
  • Patent number: 11345920
    Abstract: The invention relates to an artificial nucleic acid molecule comprising an open reading frame and a 3?-UTR comprising at least one poly(A) sequence or a polyadenylation signal. The invention also relates to a method for increasing protein production from an artificial nucleic acid molecule and to the use of a 3?-UTR for a method for increasing protein production from an artificial nucleic acid molecule. Moreover, the invention concerns the use of the artificial nucleic acid molecule as a medicament, as a vaccine or in gene therapy.
    Type: Grant
    Filed: December 5, 2021
    Date of Patent: May 31, 2022
    Assignee: CureVac AG
    Inventors: Andreas Thess, Thomas Schlake, Stefanie Grund
  • Patent number: 11345933
    Abstract: Described herein are synthetic oligonucleotides for editing a cell. The oligonucleotides described herein comprise the following covalently-linked components: (i) a nucleic acid encoding a guide RNA (gRNA) sequence targeting a target region in a cell; (ii) a region homologous to the target region comprising a change in sequence relative to the target region; and (iii) a site conferring immunity to nuclease-mediated editing.
    Type: Grant
    Filed: December 7, 2021
    Date of Patent: May 31, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: Andrew Garst, Ryan T Gill
  • Patent number: 11339427
    Abstract: Disclosed herein are methods of long range target specific amplification and sequencing using an RNA intermediate synthesized directly from the target including using hairpin adaptors having a double stranded promoter and an overhang which hybridizes with a reverse-complementary overhang on a target nucleic acid. RNA transcription eliminates clonal amplification of early synthesis errors. Approaches allow for the identification of target-adjacent sequence, such as sequence adjacent to a repeat element target. Also disclosed herein are compositions and kits for amplification and sequencing.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: May 24, 2022
    Assignee: JUMPCODE GENOMICS, INC.
    Inventor: Keith Brown
  • Patent number: 11340232
    Abstract: The present invention provides methods for constructing peptide construct sets and methods of use of these peptide construct sets in assay systems for peptide analysis, and in particular for use in high throughput peptide analysis. The methods allow for analysis of large sets of peptide constructs in a cost-effective manner, employing molecular biological techniques that are both robust and easily parallelized. Thus, the methods allow for the construction of peptide construct sets encompassing, e.g., the human proteome.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: May 24, 2022
    Assignee: Prognosys Biosciences, Inc.
    Inventors: Igor A. Kozlov, Mark S. Chee, Petr Capek, David A. Routenberg
  • Patent number: 11332797
    Abstract: Herein is reported a method for determining methylation of a promoter nucleic acid operably linked to a nucleic acid encoding a polypeptide and thereby determining the long-term productivity of a cell. Also an aspect is a method for selecting a cell for producing a polypeptide by determining the methylation of the promoter nucleic acid operably linked to the structural gene encoding the polypeptide.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: May 17, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Goepfert, Peter Becker, Benjamin Moritz
  • Patent number: 11332719
    Abstract: The present invention generally relates to methods and compositions used delivery of gene editing compositions including transcriptional effectors with parvovirus and preferred methods for making same.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 17, 2022
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Feng Zhang, Mark D. Brigham, Le Cong, Silvana Konermann
  • Patent number: 11326190
    Abstract: An aspect of the present disclosure is a microbial cell that includes a genetic modification resulting in the expression of a deficient form of an endogenous dioxygenase, and a gene encoding an exogenous dioxygenase and a promoter sequence, where the endogenous dioxygenase includes PcaH and PcaG, the exogenous dioxygenase includes LigA and LigB, the microbial cell is capable of growth utilizing at least one of a cellulose decomposition molecule or a lignin decomposition molecule, and the microbial cell is capable of producing 2-hydroxy-2H-pyran-4,6-dicarboxylic acid.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: May 10, 2022
    Assignee: Alliance for Sustainable Energy, LLC
    Inventors: Gregg Tyler Beckham, Christopher W. Johnson, Derek R. Vardon
  • Patent number: 11326212
    Abstract: The disclosure provides a method of identifying a subject as having B-cell non-Hodgkin lymphoma (NHL) such as testing a sample from a subject for a mutation in one or more biomarkers. Also described are methods for classifying or monitoring a subject having, or suspected of having, B-cell non-Hodgkin lymphoma comprising testing the sample for a mutation in one or more biomarkers.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: May 10, 2022
    Assignee: British Columbia Cancer Agency Branch
    Inventors: Ryan D. Morin, Marco A. Marra, Andrew J. Mungall, Martin Hirst, Maria Mendez-Lago, Randy D. Gascoyne, Joseph M. Connors
  • Patent number: 11319601
    Abstract: The present invention relates to cell-based assays involving HER2. The assays use assay cells that are transfected with cassettes containing the HER2 gene of interest and measure the effect of mutations on the activity of HER2, and on their response to inhibitors.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: May 3, 2022
    Assignee: Medical Diagnostic Laboratories, LLC
    Inventor: Yick Loi Raymond Yu
  • Patent number: 11319544
    Abstract: Methods and materials for genetically engineering methylotrophic yeast are provided.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: May 3, 2022
    Assignee: Impossible Foods Inc.
    Inventors: Smita Shankar, Martin Andrew Hoyt
  • Patent number: 11320422
    Abstract: Disclosed herein are methods and compositions useful for evaluating, selecting, identifying, or making a cell or cell line that has improved production capacity for generating higher yields of products and/or improved capacity to produce higher quality products. Products, as described herein, can include a polypeptide that is endogenously expressed by the cell, a recombinant polypeptide that is not endogenously expressed, or a non-naturally occurring recombinant polypeptide. The methods described herein include modulating, e.g., inhibiting, the protein degradation pathway by using a proteasome inhibitor, an ER-associated degradation (ERAD) inhibitor, or a ubiquitin pathway inhibitor.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: May 3, 2022
    Assignee: Lonza Ltd.
    Inventors: Colin Mark Jaques, Christopher Mark Smales, Tanya Jeane Knight
  • Patent number: 11312968
    Abstract: Strains of yeast genetically engineered to produce increased amounts of non-hydroxylated collagen or hydroxylated collagen are described. An all-in-one vector including the DNA necessary to produce collagen, promotors, and hydroxylating enzymes is also described. Methods for producing non-hydroxylated or hydroxylated collagen are also provided.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: April 26, 2022
    Assignee: MODERN MEADOW, INC.
    Inventors: Lixin Dai, Julia Borden, Jeffrey Nelson, Kristin Ruebling-Jass
  • Patent number: 11306299
    Abstract: The present disclosure provides compositions of matter, methods and instruments for editing nucleic acids in live yeast cells.
    Type: Grant
    Filed: November 3, 2021
    Date of Patent: April 19, 2022
    Assignee: Inscripta, Inc.
    Inventors: Skylar Stefani, Tian Tian, Miles Gander
  • Patent number: 11299539
    Abstract: Provided herein are methods of producing a polypeptide containing two chains, such as an antibody including a light chain and a heavy chain. In particular, methods are provided for producing heterologous secretory proteins in bacteria through utilization of optimized expression vectors and culture processes.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: April 12, 2022
    Assignee: Genentech, Inc.
    Inventors: James Giulianotti, Dorothea E. Reilly